Table 2. The association of Copy number variants of miR-9-3, miR-22, miR-23a, miR-143, miR-146a, miR-205 and miR-301a with Behcet’s disease and VKH syndrome.
| Genes | Stage | CNVs | VKH(frequency) | BD(frequency) | Controls(frequency) | P(VKH) | OR(95% CI) | P (BD) | OR(95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| miR-22 | Stage 1 | <2 | 5(1.3%) | 12(3.2%) | 7(1.1%) | 0.721 | 1.2(0.3–3.9) | 0.018 | 3.1(1.2–8.3) |
| =2 | 345(90.1%) | 352(94.6%) | 620(93.9%) | 0.022 | 0.6(0.4–0.9) | 0.459 | 1.2(0.7–2.2) | ||
| >2 | 33(8.6%) | 8(2.2%) | 33(5.0%) | 0.021 | 1.8(1.1–3.0) | 0.012 | 0.4(0.2–0.8) | ||
| miR-143 | Stage 1 | <2 | 2(0.5%) | 0(0.0%) | 1(0.2%) | 0.279 | 3.5(0.3–38.5) | — | — |
| =2 | 375(98.4%) | 368(99.2%) | 647(98.0%) | 0.647 | 1.3(0.5–3.3) | 0.084 | 2.9(0.8–10.3) | ||
| >2 | 4(1.0%) | 3(0.8%) | 12(1.8%) | 0.332 | 0.6(0.2–1.8) | 0.116 | 0.4(0.1–1.3) | ||
| miR-205 | Stage 1 | <2 | 5(1.3%) | 0(0.0%) | 3(0.5%) | 0.13 | 2.9(0.7–12.2) | — | — |
| =2 | 369(96.3%) | 358(98.6%) | 650(98.6%) | 0.015 | 0.4(0.2–0.9) | 0.988 | 1.0(0.3–3.0) | ||
| >2 | 9(2.3%) | 5(1.4%) | 6(0.9%) | 0.06 | 2.6(0.9–7.4) | 0.489 | 1.5(0.5–5.0) | ||
| miR-9-3 | Stage 1 | <2 | 14(3.7%) | 26(6.9%) | 29(4.4%) | 0.574 | 0.8(0.4–1.6) | 0.084 | 1.6(0.9–2.8) |
| =2 | 263(69.0%) | 267(70.8%) | 434(65.8%) | 0.28 | 1.2(0.9–1.5) | 0.094 | 1.3(1.0–1.7) | ||
| >2 | 104(27.3%) | 84(22.3%) | 197(29.8) | 0.382 | 0.9(0.7–1.2) | 0.008 | 0.7(0.5–0.9) | ||
| miR-23a | Stage 1 | <2 | 3(0.8%) | 3(0.8%) | 0(0.0%) | — | — | — | — |
| =2 | 339(90.9%) | 342(92.2%) | 640(97.0%) | 2.44 × 10−5 | 0.3(0.2–0.6) | 0.003 | 0.4(0.2–0.8) | ||
| >2 | 31(8.3%) | 26(7.0%) | 20(3.0%) | 2.00 × 10−4 | 2.9(1.6–5.2) | 0.011 | 2.2(1.2–4.0) | ||
| Stage 2 | <2 | 9(1.0%) | 15(0.9%) | 0.758 | 1.1(0.5–2.6) | ||||
| =2 | 790(91.9%) | 1559(95.6%) | 1.30 × 10−4 | 0.5(0.4–0.7) | |||||
| >2 | 61(7.1%) | 57(3.5%) | 5.83 × 10−5 | 2.1(1.5–3.1) | |||||
| Combined | <2 | 12(1.0%) | 15(0.7%) | 0.301 | 1.5(0.7–3.2) | ||||
| =2 | 1129(91.6%) | 2199(96.0%) | 4.79 × 10−8 | 0.5(0.3–0.6) | |||||
| >2 | 92(7.5%) | 77(3.4%) | 5.83 × 10−8 | 2.3(1.7–3.2) | |||||
| miR-146a | Stage 1 | <2 | 5(1.3%) | 0(0.0%) | 3(0.5%) | 0.129 | 2.9(0.7–12.2) | ||
| =2 | 350(91.4%) | 361(99.4%) | 656(99.4%) | 1.57 × 10−11 | 0.1(0.02–0.2) | 0.912 | 1.1(0.2–6.0) | ||
| >2 | 28(7.3%) | 2(0.6%) | 1(0.2%) | 1.21 × 10−11 | 52.0(7.0–383.6) | 0.258 | 3.7(0.3–40.4) | ||
| Stage 2 | <2 | 59(6.9%) | 77(4.8%) | 0.032 | 1.5(1.0–2.1) | ||||
| =2 | 679(79.4%) | 1470(92.0%) | 2.12 × 10−19 | 0.3(0.3–0.4) | |||||
| >2 | 117(13.7%) | 51(3.2%) | 1.08 × 10−22 | 4.8(3.4–6.8) | |||||
| Combined | <2 | 64(5.2%) | 80(3.5%) | 0.021 | 1.5(1.1–2.1) | ||||
| =2 | 1029(83.1%) | 2126(94.2%) | 7.11 × 10−26 | 0.3(0.2–0.4) | |||||
| >2 | 145(11.7%) | 52(2.3%) | 8.43 × 10−31 | 5.6(4.1–7.8) | |||||
| miR-301a | Stage 1 | <2 | 19(5.0%) | 11(2.9%) | 9(1.4%) | 4.71 × 10−4 | 3.8(1.7–8.5) | 0.078 | 2.2(0.9–5.3) |
| =2 | 352(92.9%) | 357(95.2%) | 645(97.7%) | 1.32 × 10−4 | 0.3(0.2–0.6) | 0.026 | 0.5(0.2–0.9) | ||
| >2 | 8(2.1%) | 7(1.9%) | 6(0.9%) | 0.106 | 2.4(0.8–6.8) | 0.184 | 2.1(0.7–6.2) | ||
| Stage 2 | <2 | 41(4.8%) | 30(1.9%) | 3.87 × 10−5 | 2.6(1.6–4.3) | ||||
| =2 | 792(93.2%) | 1543(97.0%) | 1.10 × 10−5 | 0.4(0.3–0.6) | |||||
| >2 | 17(2.0%) | 18(1.1%) | 0.085 | 1.8(0.9–3.5) | |||||
| Combined | <2 | 60(4.9%) | 39(1.7%) | 9.23 × 10−8 | 2.9(1.9–4.4) | ||||
| =2 | 1144(93.1%) | 2188(97.2%) | 8.77 × 10−9 | 0.4(0.3–0.5) | |||||
| >2 | 25(2.0%) | 24(1.1%) | 0.021 | 1.9(1.1–3.4) |
Bonferroni correction for the number of CNVs tested by the conditional analysis, P value less than 0.05/21 = 0.0024 was supposed significant. Discrepancy between numbers of individuals is due to missing genotyping data.